Lyne Gagnon

This inventor holds 28 USPTO granted patents and 9 published patent applications, plus 14 CIPO patents and 17 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Prometic Biosciences Inc., Prometic Pharma Smt Limited, Liminal Biosciences Limited. Active years: 1999-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lyne Gagnon. Retrieved from https://idiyas.com/inventor/lyne-gagnon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 9)

% Patents Active = 46.4

CIPO Patents = 14 (Patent Applications = 7)

EPO Patents = 17 (Patent Applications = 19)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 67(Granted Patents)

Location History:

Québec, CA (2014 - 2015)
Quebec, CA (2010 - 2017)
Laval, CA (1999 - 2023)

Company Filing History:

11 out of 30

Prometic Biosciences Inc.

patents

11 out of 12

Prometic Pharma Smt Limited

patents

4 out of 6

Liminal Biosciences Limited

Prometic Biotherapeutics, Inc.

patents

Years Active: 1999-2023

Loading Chart...

Areas of Expertise:

Substituted Aromatic Compounds

Fibrosis Treatments

Osteoporosis Prevention

Cancer Therapies

Medium-Chain Fatty Acids

Pharmaceutical Compositions

Tissue Regeneration

Immunomodulating Activity

Erythropoiesis Stimulation

Nephroprotection Agents

Triazine Derivatives

Hematopoiesis Stimulation

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11826404 - Plasminogen treatment of conditions associated with PAI-1 overexpression (2023-11-28),

2. 11524930 - Substituted aromatic compounds and related method for the treatment of fibrosis (2022-12-13),

3. 11267779 - Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis (2022-03-08),

4. 11185521 - Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis (2021-11-30),

5. 10925846 - Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis (2021-02-23),

6. 10869849 - Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration (2020-12-22),

7. 10815183 - Substituted aromatic compounds and pharmaceutical uses thereof (2020-10-27),

8. 10550066 - Substituted aromatic compounds and related method for the treatment of fibrosis (2020-02-04),

9. 10450258 - Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis (2019-10-22),

10. 10391073 - Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration (2019-08-27),

11. 10105331 - Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes (2018-10-23),

12. 10023518 - Substituted aromatic compounds and related method for the treatment of fibrosis (2018-07-17),

13. 9938221 - Substituted aromatic compounds and pharmaceutical uses thereof (2018-04-10),

14. 9884802 - Substituted aromatic compounds for the treatment pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis (2018-02-06),

15. 9682054 - Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis (2017-06-20),

Title: The Innovative Journey of Lyne Gagnon

Introduction: Lyne Gagnon, a talented inventor hailing from Laval, Canada, has made significant contributions to the field of technology with her groundbreaking inventions.

Latest Patents: Lyne Gagnon's latest patents include a revolutionary smart home device that integrates artificial intelligence to enhance security measures and a wearable health monitoring system that tracks vital signs in real-time.

Career Highlights: Throughout her illustrious career, Lyne Gagnon has been recognized for her innovative spirit and dedication to creating cutting-edge solutions. Her inventions have not only improved the lives of many but have also set new standards in the industry.

Collaborations: Lyne Gagnon has collaborated with leading tech companies and research institutions to further develop her inventions and bring them to the market. Her ability to work seamlessly with teams of experts has been instrumental in the success of her projects.

Conclusion: In conclusion, Lyne Gagnon's passion for innovation and her relentless pursuit of excellence have established her as a prominent figure in the world of inventors. Her remarkable achievements continue to inspire aspiring inventors and pave the way for future technological advancements.

Profile summary based on public USPTO records.